Promomed expands product portfolio
Promomed 04 May 2021
In April 2021, Promomed's product portfolio was replenished with three new drug products. The Ministry of Health of the Russian Federation has issued marketing authorization certificates for a capsulated broad-spectrum antibiotic Cefixime, a non-depolarizing muscle relaxant Rocuronium bromide (solution for intravenous administration) and an antiseptic cream for external use Dexpanthenol+Chlorhexidine.
The new drugs will be produced at the production base of Biokhimik JSC in Saransk starting from the second half of 2021.
Promomed Group receives patent for injectable form of antiviral drug Areplivir® (favipiravir)
Petr Bely – winner of the “2022 Person of the Year” award in the “Entrepreneur Pharma” nomination